RXRX - Is This Under-the-Radar Artificial Intelligence (AI) Stock a Buy?
2024-04-04 08:45:00 ET
Artificial intelligence (AI) will revolutionize the way many companies do business. It could even fundamentally change entire industries. Picking the corporations driving these changes could pay off massive dividends -- literally and figuratively -- down the road.
Though plenty of high-profile companies are looking to get in on the act, let's consider one relatively small and unknown player seeking to make a dent: Recursion Pharmaceuticals (NASDAQ: RXRX) . This mid-cap biotech has big ideas, but are the company's shares worth buying?
Developing and marketing novel drugs is a painfully slow process. It is also risky; most therapies tested on humans never earn regulatory approval. Meanwhile, thousands of patients suffer and die while waiting for a medicine that could have eased their pain. Recursion wants to change that. The company uses an AI-powered operating system (OS) to test how millions of clinical compounds would interact with the human body and possibly treat various illnesses.
For further details see:
Is This Under-the-Radar Artificial Intelligence (AI) Stock a Buy?